🔎 Trials Near Me

Home › Non-Small Cell Lung Cancer › Arkansas › Little Rock

Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Little Rock, AR

Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Little Rock. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Nagre-recruitPhase 2
  • University of Arkansas for Medical Sciences /ID# 272923, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06568939

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Nagre-recruitPhase 3
  • UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06312137

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Nagre-recruitPhase 2
  • CARTI Cancer Center, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03191149

Pan-tumor MRD Study

Nagre-recruitObservasyonal na pag-aaral
  • CARTI, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06605404

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Nagre-recruitPhase 2
  • Research Site, Little Rock
Edad 18 hanggang 95 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05061550

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Nagre-recruitPhase 3
  • CARTI Cancer Center ( Site 0006), Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06422143

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Nagre-recruitPhase 3
  • University of Arkansas for Medical Sciences, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06500481

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Nagre-recruitPhase 1
  • University of Arkansas, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT07444814

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Nagre-recruitPhase 2
  • University of Arkansas for Medical Sciences, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2
  • University of Arkansas for Medical Sciences, Little Rock
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2
  • University of Arkansas for Medical Sciences, Little Rock
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Nagre-recruitObservasyonal na pag-aaral
  • Massive Bio SYNERGY-AI site, Little Rock
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod

Iba pang pag-aaral sa Little Rock

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.